Herve Hoppenot Incyte Corp (INCY) insider trading activity

Herve Hoppenot is Director of INCYTE CORP. Currently has a direct ownership of 326,803 shares of INCY, which is worth approximately $34 Million. The most recent transaction as insider was on Dec 08, 2025, when has been sold 2,843 shares (Common Stock) at a price of $96.7 per share, resulting in proceeds of $274,918. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 327K

36.81% 3M change

34.2% 12M change

Total Value Held $34 Million

Herve Hoppenot Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 08 2025	SELL Payment of exercise price or tax liability	$274,918 $96.7 p/Share	2,843 Reduced 0.86%	326,803 Common Stock
Nov 10 2025	SELL Open market or private sale	$19,773,750 $105.46 p/Share	187,500 Reduced 36.26%	329,646 Common Stock
Jul 15 2025	SELL Payment of exercise price or tax liability	$321,662 $68.25 p/Share	4,713 Reduced 0.9%	517,146 Common Stock
Jul 14 2025	SELL Payment of exercise price or tax liability	$347,170 $69.98 p/Share	4,961 Reduced 0.94%	521,859 Common Stock
Jul 02 2025	SELL Payment of exercise price or tax liability	$2,915,562 $68.17 p/Share	42,769 Reduced 7.51%	526,820 Common Stock
Jun 26 2025	BUY Grant, award, or other acquisition	-	6,016 Added 1.05%	569,589 Common Stock
Apr 01 2025	BUY Grant, award, or other acquisition	-	66,899 Added 10.61%	563,573 Common Stock

Jul 15 2024	SELL Payment of exercise price or tax liability	$318,744 $64.25 p/Share	4,961 Reduced 0.99%	496,674 Common Stock
Jul 15 2024	BUY Grant, award, or other acquisition	-	41,025 Added 7.56%	501,635 Common Stock
Jul 02 2024	SELL Payment of exercise price or tax liability	$2,462,491 $59.02 p/Share	41,723 Reduced 8.31%	460,610 Common Stock
Feb 14 2024	BUY Grant, award, or other acquisition	-	41,577 Added 7.64%	502,333 Common Stock
Jul 14 2023	BUY Grant, award, or other acquisition	-	43,184 Added 9.03%	434,856 Common Stock
Jul 03 2023	SELL Payment of exercise price or tax liability	$2,698,431 $62.08 p/Share	43,467 Reduced 9.99%	391,672 Common Stock
Jan 20 2023	BUY Grant, award, or other acquisition	-	29,196 Added 6.29%	435,139 Common Stock
Jul 05 2022	SELL Payment of exercise price or tax liability	$1,678,040 $79.25 p/Share	21,174 Reduced 4.96%	405,943 Common Stock
Jul 02 2022	BUY Grant, award, or other acquisition	-	60,433 Added 12.4%	427,117 Common Stock
Nov 19 2021	BUY Grant, award, or other acquisition	-	15,506 Added 4.3%	345,383 Common Stock
Jul 06 2021	SELL Payment of exercise price or tax liability	$130,177 $83.34 p/Share	1,562 Reduced 0.47%	329,877 Common Stock
Jul 02 2021	SELL Payment of exercise price or tax liability	$1,344,719 $83.58 p/Share	16,089 Reduced 4.63%	331,439 Common Stock
Jul 02 2021	BUY Grant, award, or other acquisition	-	44,264 Added 11.3%	347,528 Common Stock
Feb 23 2021	BUY Open market or private purchase	$1,000,007 $77.37 p/Share	12,925 Added 4.35%	284,231 Common Stock
Nov 16 2020	BUY Grant, award, or other acquisition	-	7,225 Added 2.59%	271,306 Common Stock

Also insider at

BCYC

BICYCLE THERAPEUTICS plc Healthcare

MAZE

Maze Therapeutics, Inc.

Herve Hoppenot

Director

Wilmington, DE

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells INCY shares.

Notify only if

Value

Insider Trading

Get notified when an Incyte Corp insider buys or sells INCY shares.

Notify only if

Operation

Value

Type

News

Receive news related to INCYTE CORP

Track Activities on INCY

Account